Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dextenza with iLUX for MGD and Evaporative Dry Eye
NCT04658927Phase 4Completed
- Sponsor
- Warrenville EyeCare & LASIK
- Start
- Jan 2021
- Primary completion
- Jan 2021
- Modality
- Implantable Devices, Implantable Hydrogels, Small Molecules
- Countries
- 1
01
Overview
Phase 4, single-blind trial of ozurdex in meibomian gland dysfunction (MGD) and dry eye syndrome (DED) (3 arms), sponsored by Warrenville EyeCare & LASIK. Primary endpoints: Change in Meibomian gland score at 12 weeks and Patient satisfaction with treatment at 12 weeks. Started Jan 2021; status: completed.
02
Drugs
ozurdex
03
Conditions
meibomian gland dysfunction (MGD)dry eye syndrome (DED)
Beyond the preview
Go deeper on NCT04658927.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04658927.